Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...

Groundbreaking Harvard research reveals gut-produced molecules significantly influence obesity and blood sugar control. These ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

Inflammation likely plays a key role in T2D outcomes, and various anti-inflammatory treatments may improve both T2D and its ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...

Recent clinical research indicates that semaglutide may effectively reverse weight gain and blood sugar issues caused by ...

MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...

The managing director of Novo Nordisk India on Ozempic’s delayed launch in India, leading the fight against diabetes and ...

Danish Novo Nordisk launched its blockbuster treatment injection Ozempic in three forms in 0.25 mg, 0.5 mg and 1 mg in the ...